Trial reportHaematologica2014
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
Registry-linked trialAbstract readClinical Trial, Phase IILetter
In one paragraph
Trial report in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01248455 (A Phase II Trial of IPH2101), which is not on this map. Cited by 75 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Trial of IPH2101 (Anti-KIR) in Smoldering Multiple Myeloma (SMM)
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Emerging immune targets for the treatment of multiple myeloma.Immunotherapy · 2018Pooled it
- Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.Frontiers in immunology · 2019Trial
- Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Trial
- Innate immune cells in chimeric antigen receptor therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Review
- Article
- Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.Journal of experimental & clinical cancer research : CR · 2025Review
- Advances in the role of NK cells in MDS immune dysfunction and antitumor research.Frontiers in immunology · 2025Review
- Review
- Real-time ex vivo monitoring of NK cell migration toward obesity-associated oesophageal adenocarcinoma following modulation of CX3CR1.Scientific reports · 2024Article
- Exploiting innate immunity for cancer immunotherapy.Molecular cancer · 2023Review
- Innate lymphoid cells and innate-like T cells in cancer - at the crossroads of innate and adaptive immunity.Nature reviews. Cancer · 2023Review
- Diversity of immune checkpoints in cancer immunotherapy.Frontiers in immunology · 2023Review
- Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity.Frontiers in immunology · 2023Article
- Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.International journal of molecular sciences · 2022Review
- Review
- Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion.JCI insight · 2022Article
- Novel immunotherapies in multiple myeloma.International journal of hematology · 2022Review
- Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.Frontiers in immunology · 2022Review
- Natural killer cells: the next wave in cancer immunotherapy.Frontiers in immunology · 2022Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Neha KordeMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mattias CarlstenHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Min-Jung LeeMedical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Alex MinterMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Walter Reed National Military Medical Center, National Institutes of Health, Bethesda, MD, USA.
Esther TanMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Walter Reed National Military Medical Center, National Institutes of Health, Bethesda, MD, USA.
Mary KwokMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Walter Reed National Military Medical Center, National Institutes of Health, Bethesda, MD, USA.
Elisabet ManasanchMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Manisha BhutaniMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nishant TagejaMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mark RoschewskiMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Adriana ZingoneMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Rene CostelloMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Marcia MulquinMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Diamond ZuchlinskiMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Irina MaricDept. of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Katherine R CalvoDept. of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Raul BraylanDept. of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Prashant TembhareFlow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Constance YuanFlow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Maryalice Stetler-StevensonFlow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jane TrepelMedical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Richard ChildsHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Ola LandgrenMultiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA landgrec@mskcc.org.
Funding
Allogeneic Immunotherapy for cancer and nonmalignant hematological disordersZIAHL002345 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHILDS, RICHARD · 2009 to 2025
$53.3MSignal Transduction Events and the Regulation of Cell GrowthZICSC006743 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI TREPEL, JANE B · 2009 to 2023
$13.8MFlow Cytometric Evaluation of BiomarkersZICBC011104 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, HAO-WEI · 2009 to 2025
$8.6MCollaboration with Investigators from the Multiple Myeloma Section, Medical Oncology Branch, NCI and of the Molecular Medicine Branch, Molecular Genomics & Therapeutics Section, NIDDKZIACL060089 · CLC · CLINICAL CENTER · PI BRAYLAN, RAUL · 2014 to 2015
$0kThe Role of microRNA in Hematologic MalignanciesZIACL090025 · CLC · CLINICAL CENTER · PI CALVO, KATHERINE · 2010 to 2025
$0kBone Marrow Histopathological Changes in Neoplastic and Non-Neoplastic DiseasesZIACL090027 · CLC · CLINICAL CENTER · PI MARIC, IRINA · 2010 to 2025
$0kAbstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsHumansMultiple MyelomaReceptors, KIRTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsIPH-2101Receptors, KIRclinical responseHLA-C binding KIR2D reportsIPH2101KIR2D blockadeNK-cell functionsmoldering multiple myeloma
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT01248455ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.